Maze Therapeutics, Inc. operates as a clinical-stage biopharmaceutical firm, concentrating on the creation of precise small molecule medications for a range of ailments within the United States. Its primary therapeutic targets encompass renal, cardiovascular, and associated metabolic conditions, alongside obesity. The company's developmental pipeline highlights two leading drug candidates: MZE829, an oral small molecule engineered to inhibit apolipoprotein L1, which is currently in Phase II clinical studies for APOL1 kidney disease; and MZE782, another oral small molecule designed to block the solute transporter SLC6A19, presently in Phase I clinical evaluation for chronic kidney disease.